Based on 6 analysts giving stock ratings to Artiva Biotherapeutics Inc in the past month.
In the current month, ARTV has received 2 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. ARTV average Analyst price target in the last month is 20.750.
Based on analysts' estimates, ARTV EPS is projected to reach -0.576 in FY2026Q4, following reported EPS of -0.563 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
The market expectation was USD -0.56, while Artiva Biotherapeutics IncARTV's earnings per share (EPS) for the previous quarter was USD -0.63. EPS for the next quarter is expected at USD -0.58.